Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A CD25-biased interleukin-2 for autoimmune therapy engineered via a semi-synthetic organism.
Ptacin JL, Ma L, Caffaro CE, Acuff NV, Germar K, Severy P, Qu Y, Vela JL, Cai X, San Jose KM, Aerni HR, Chen DB, Esche E, Ismaili TK, Herman R, Pavlova Y, Pena MJ, Nguyen J, Koriazova LK, Shawver LK, Joseph IB, Mooney J, Peakman M, Milla ME. Ptacin JL, et al. Among authors: milla me. Commun Med (Lond). 2024 Mar 26;4(1):58. doi: 10.1038/s43856-024-00485-z. Commun Med (Lond). 2024. PMID: 38532017 Free PMC article.
Distinct Predictive Immunogenomic Profiles of Response to Immune Checkpoint Inhibitors and IL2: A Real-world Evidence Study of Patients with Advanced Renal Cancer.
Eisner JR, Beebe KD, Mayhew GM, Shibata Y, Guo Y, Farhangfar C, Farhangfar F, Uronis JM, Mooney J, Milburn MV, Foureau D, White RL, Amin A, Milla ME. Eisner JR, et al. Among authors: milla me. Cancer Res Commun. 2022 Aug 30;2(8):894-903. doi: 10.1158/2767-9764.CRC-21-0153. eCollection 2022 Aug. Cancer Res Commun. 2022. PMID: 36923304 Free PMC article.
The Immunogenomic Landscape of Peripheral High-Dose IL-2 Pharmacodynamics in Patients with Metastatic Renal Cell Carcinoma: A Benchmark for Next-Generation IL-2-Based Immunotherapies.
Beebe KD, Eisner JR, Guo J, Shibata Y, Davison JM, Uronis J, Farhangfar C, Farhangfar F, Mooney J, Milburn MV, White RL, Amin A, Milla ME, Foureau DM. Beebe KD, et al. Among authors: milla me. J Immunol. 2024 May 20:ji2300736. doi: 10.4049/jimmunol.2300736. Online ahead of print. J Immunol. 2024. PMID: 38767437
An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism.
Ptacin JL, Caffaro CE, Ma L, San Jose Gall KM, Aerni HR, Acuff NV, Herman RW, Pavlova Y, Pena MJ, Chen DB, Koriazova LK, Shawver LK, Joseph IB, Milla ME. Ptacin JL, et al. Among authors: milla me. Nat Commun. 2021 Aug 9;12(1):4785. doi: 10.1038/s41467-021-24987-9. Nat Commun. 2021. PMID: 34373459 Free PMC article.
A Single Amino Acid Difference between Mouse and Human 5-Lipoxygenase Activating Protein (FLAP) Explains the Speciation and Differential Pharmacology of Novel FLAP Inhibitors.
Blevitt JM, Hack MD, Herman K, Chang L, Keith JM, Mirzadegan T, Rao NL, Lebsack AD, Milla ME. Blevitt JM, et al. Among authors: milla me. J Biol Chem. 2016 Jun 10;291(24):12724-12731. doi: 10.1074/jbc.M116.725325. Epub 2016 Apr 16. J Biol Chem. 2016. PMID: 27129215 Free PMC article.
Phenotyping drug polypharmacology via eicosanoid profiling of blood.
Song J, Liu X, Rao TS, Chang L, Meehan MJ, Blevitt JM, Wu J, Dorrestein PC, Milla ME. Song J, et al. Among authors: milla me. J Lipid Res. 2015 Aug;56(8):1492-500. doi: 10.1194/jlr.M058677. Epub 2015 May 28. J Lipid Res. 2015. PMID: 26022804 Free PMC article.
48 results